⌕
UroGen Pharma · URGN · Nasdaq
Tenet 44 · Weak
Compare
$29.87+6.30%At closeTenet 44 · Weak
$29.87+1.77 (+6.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

UroGen Pharma (URGN) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (13 new · 28 increased · 10 reduced · 0 closed · 16 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 67 filers, Sep 30, 2026
# 13F FUNDS
67
13F VALUE
$163.2M
4.0M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 8, 2026Degnan ChrisChief Financial OfficerAcquired · Option exercise4,483—↗
Oct 8, 2026Degnan ChrisChief Financial OfficerDisposed · Open-market sale2,202$36.69↗
Oct 8, 2026Degnan ChrisChief Financial OfficerDisposed · Option exercise4,483Restricted Stock Units—↗
Sep 8, 2026Schoenberg MarkChief Medical OfficerDisposed · Open-market sale871$42.92↗
Sep 8, 2026Smith Jason DrewGeneral CounselDisposed · Open-market sale1,519$42.54↗
Sep 7, 2026Schoenberg MarkChief Medical OfficerAcquired · Option exercise1,667—↗
Sep 7, 2026Schoenberg MarkChief Medical OfficerDisposed · Option exercise1,667Restricted Stock Units—↗
Sep 7, 2026Smith Jason DrewGeneral CounselAcquired · Option exercise3,334—↗
Sep 7, 2026Smith Jason DrewGeneral CounselDisposed · Option exercise3,334Restricted Stock Units—↗
Aug 26, 2026Robinson James A. Jr.directorAcquired · Option exercise2,000—↗
Aug 26, 2026Robinson James A. Jr.directorDisposed · Option exercise2,000Restricted Stock Unit—↗
Aug 20, 2026Schoenberg MarkChief Medical OfficerDisposed · Open-market sale60,677$47.05↗
Jul 9, 2026Schoenberg MarkChief Medical OfficerDisposed · Open-market sale10,000$40.00↗
Jun 22, 2026Schoenberg MarkChief Medical OfficerDisposed · Open-market sale10,000$35.01↗
Jun 22, 2026Wildman Daniel GeorgedirectorAcquired · Grant / award10,000Stock Option (right ot buy)—↗
Jun 22, 2026Wildman Daniel GeorgedirectorAcquired · Grant / award8,000Restricted Stock Unit—↗
Jun 22, 2026Robinson James A. Jr.directorAcquired · Grant / award10,000Stock Option (right ot buy)—↗
Jun 22, 2026Robinson James A. Jr.directorAcquired · Grant / award8,000Restricted Stock Unit—↗
Jun 22, 2026Holden StuartdirectorAcquired · Grant / award20,000Stock Option (right ot buy)—↗
Jun 22, 2026BUTITTA CYNTHIA MdirectorAcquired · Grant / award10,000Stock Option (right ot buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold UroGen Pharma?

UroGen Pharma was held by 67 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.